Topotecan (Hycamtin)

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.

Also Known As:

Hycamtin; 9-Dimethylaminomethyl-10-hydroxycamptothecin; Hycamtamine; NSC-609699; Nogitecan Hydrochloride; SK&F-104864-A; SKF-104864-A; Topotecan Hydrochloride; Topotecan Monohydrochloride, (S)-Isomer; 9 Dimethylaminomethyl 10 hydroxycamptothecin; Hydrochloride, Nogitecan; Hydrochloride, Topotecan; NSC 609699; NSC609699; SK&F 104864 A; SK&F104864A; SKF 104864 A; SKF104864A

Networked: 1981 relevant articles (256 outcomes, 746 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 207
- Alkaloids: 5592
  - Camptothecin: 2066
    - Topotecan: 1981

Experts

1.	Stewart, Clinton F: 31 articles (11/2023 - 03/2002)
2.	Pommier, Yves: 26 articles (03/2024 - 08/2002)
3.	Abramson, David H: 23 articles (03/2023 - 08/2007)
4.	Januchowski, Radosław: 18 articles (09/2023 - 01/2013)
5.	Schaiquevich, Paula: 18 articles (12/2018 - 11/2007)
6.	Lavrik, Olga I: 15 articles (01/2024 - 12/2018)
7.	Nowicki, Michał: 15 articles (09/2023 - 01/2014)
8.	Zakharenko, Alexandra L: 14 articles (01/2024 - 12/2018)
9.	Zabel, Maciej: 14 articles (04/2021 - 07/2012)
10.	Doroshow, James H: 13 articles (01/2023 - 02/2010)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2007 - "The broad clinical effectiveness and manageable toxicity of topotecan in other human malignancies as well as promising recent study results suggest that it is highly effective in treating cervical tumors. " 12/01/2004 - "Topotecan given as a weekly bolus is a highly active and well-tolerated treatment regimen for relapsed ovarian and primary peritoneal cancer and thus deserves further evaluation." 09/27/2001 - "The in vivo antitumor efficacy of the most potent analogue (15) was evaluated in direct comparison with topotecan using human lung tumor xenograft models. " 10/01/2004 - "Concomitant with HIF-1alpha inhibition, topotecan caused a significant tumor growth inhibition associated with a marked decrease of angiogenesis and expression of HIF-1 target genes in tumor tissue. " 12/01/2021 - "Importantly, inhaled topotecan showed superior efficacy in suppressing lung tumors at distant sites. "
2.	Ovarian Neoplasms (Ovarian Cancer) 03/01/2009 - "The peer-reviewed literature reports that topotecan is an effective, well tolerated treatment option for relapsed ovarian cancer." 03/01/1996 - "Trial of topotecan as first-line treatment for ovarian cancer announced." 08/01/2005 - "Weekly topotecan may be an appropriate treatment option for patients with recurrent ovarian cancer, especially heavily pretreated patients who might require dosing schedules with improved tolerability." 12/01/2004 - "To retrospectively investigate the safety and efficacy of weekly topotecan in heavily pretreated patients with ovarian cancer. " 10/01/2004 - "Recently, topotecan has been studied on a weekly dosing schedule for the treatment of ovarian cancer and found to have efficacy with reduced toxicity. "
3.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/17/2010 - "Intravenous topotecan was at least as effective as CAV in the treatment of patients with recurrent small-cell lung cancer and resulted in improved quality-of-life with respect to several symptoms. " 12/01/2004 - "In patients with recurrent small-cell lung cancer, who frequently present with a compromised PS, the use of topotecan as a single agent led to an improvement in PS in approximately one third of these patients without excessive toxicities. " 01/01/2004 - "Topotecan in the first-line treatment of small cell lung cancer." 05/01/2002 - "[A case of recurrent small cell lung cancer with symptoms improved by nogitecan hydrochloride]." 08/01/2022 - "In the present study we investigated how SLFN11 expression regulated the sensitivity of small cell lung cancer to topotecan. "
4.	Neuroblastoma 06/20/2005 - "Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach." 11/01/2023 - "The study objectives were to update our topotecan population pharmacokinetic model, to evaluate the feasibility of determining individual topotecan clearance using a single blood sample, and to apply this approach to topotecan data from a neuroblastoma trial to explore exposure-response relationships. " 11/01/2023 - "Phase II study of 131 I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP." 11/20/2011 - "Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study." 01/01/2008 - "The study aims to use mathematical modeling and simulation to assess the relative contribution of topotecan systemic exposure and scheduling in the activity and myelosuppression of topotecan in pediatric patients with neuroblastoma. "
5.	Retinoblastoma (Glioblastoma, Retinal) 01/01/2018 - "Three-weekly intravitreal topotecan appears effective and safe in controlling focal or diffuse refractory or recurrent vitreous seeds in retinoblastoma." 05/02/2024 - "To study the long-term safety and efficacy of intravitreal topotecan (IVT) against vitreous seeds in eyes with retinoblastoma and risk factors for their recurrence. " 12/01/2018 - "The purpose of this study is to evaluate the efficacy of periocular topotecan (POT) in the management of vitreous seeds in retinoblastoma. " 01/01/2022 - "Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study." 01/01/2018 - "To evaluate the efficacy of intravitreal topotecan for refractory or recurrent vitreous seeds in retinoblastoma. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Cisplatin (Platino)
3.	Platinum
4.	Carboplatin (JM8)
5.	Irinotecan (Camptosar)
6.	Etoposide (VP 16)
7.	Cyclophosphamide (Cytoxan)
8.	Topoisomerase I Inhibitors
9.	Vincristine (Oncovin)
10.	Gemcitabine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Aftercare (After-Treatment)